The Ludwig Institute for Cancer Research

4-Antibody has established a multi-target R&D collaboration with the Ludwig Institute for Cancer Research (LICR) at its in New York branch at the Memorial Sloan Kettering Cancer Center.  The goal of the collaboration is to apply 4-Antibody’s high throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibodies against a series of disease targets with key roles in the suppression of immune responses in cancer patients.  LICR will then take these antibody drugs into early clinical testing with the specific clinical goal of demonstrating the feasibility of reversing immunosuppression in cancer. At the point at which the programmes have achieved agreed technical milestones, 4-Antibody will seek pharmaceutical partnerships for the emerging product opportunities.

LICR (www.licr.org) has focused its worldwide clinical research efforts in cancer immunology and has built a highly significant and world renowned expertise in the monitoring of patient immunological responses in cancer immunotherapy settings.  The Institute has a long history of conducting innovative clinical research in the field of cancer immunotherapy.  The concept of reversing tolerance in cancer has been clinically validated with the recent approval of an anti-CTLA4 antibody.

Four targets have been included so far in this R&D collaboration and the first two programs address the targets GITR and OX40.